Mammary Cell News Volume 5.19 | May 16 2013

LABORATORY RESEARCH

Therapeutic Efficacy of Metronomic Chemotherapy with Cyclophosphamide and Doxorubicin on Murine Mammary Adenocarcinomas
The authors investigated the therapeutic efficacy of metronomic cyclophosphamide combined with doxorubicin in two mouse mammary adenocarcinoma models. [Ann Oncol] Abstract

Tumor Necrosis Factor Alpha Induced Warburg-Like Metabolism and Is Reversed by Anti-Inflammatory Curcumin in Breast Epithelial Cells
Researchers illustrated that treatment of non-malignant and malignant breast epithelial cells with low-level tumor necrosis factor alpha significantly increased glycolytic reliance, lactate export, and expression of the glucose transporter, GLUT1. [Int J Cancer] Abstract

The Expression and Significance of Insulin-Like Growth Factor-1 Receptor and Its Pathway on Breast Cancer Stem/Progenitors
Cancer stem cells (CSCs) are a subpopulation within cancer cells which participate in tumor initiation, radio/chemoresistance and metastasis. In breast cancer, breast CSCs (BCSCs) were identified as CD24-CD44+ cells or cells with high intracellular aldehyde dehydrogenase activity. Elucidation of the role of insulin-like growth factor-1 in breast cancer stem cells (BCSCs) is crucial to the design of breast cancer therapies targeting BCSCs. [Breast Cancer Res] Abstract | Full Article

c-MYC Regulated miR-23a~24-2~27a Cluster Promotes Mammary Carcinoma Cell Invasion and Hepatic Metastasis by Targeting Sprouty2
Investigators observed that the expression levels of microRNA (miR)-23a, miR-24-2 and miR-27a were significantly higher in breast cancer with lymph node metastasis, compared with that from patients without lymph node metastasis or normal tissue. Forced expression of the miR-23a~24-2~27a cluster promoted mammary carcinoma cell migration, invasion and hepatic metastasis, through targeting Sprouty2, and consequent activation of p44/42 MAPK. [J Biol Chem] Abstract | Full Article

Fusion of CCL21 Non-Migratory Active Breast Epithelial and Breast Cancer Cells Give Rise to CCL21 Migratory Active Tumor Hybrid Cell Lines
Scientists investigated M13HS hybrid cell lines, derived from spontaneous fusion events between M13SV1-EGFP-Neo breast epithelial cells exhibiting stem cell characteristics and HS578T-Hyg breast cancer cells, concerning CCL21/CCR7 signaling. [PLoS One] Full Article

BMP4 Is a Novel Transcriptional Target and Mediator of Mammary Cell Migration Downstream of the Hippo Pathway Component TAZ
Researchers provide convincing evidence that overexpression of TAZ in a mammary epithelial cell line, MCF10A, leads to enhanced cell migration – a fundamental characteristic of the metastatic progression of cancers. In addition, they identified the secreted growth factor BMP4 as mediating TAZ-induced cell migration. [Cell Signal] Abstract

CLINICAL RESEARCH

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
The Oncotype DX breast cancer assay was performed for patients with ductal carcinoma in situ (DCIS) treated with surgical excision without radiation in the Eastern Cooperative Oncology Group E5194 study. The association of the prospectively defined DCIS Score (calculated from seven cancer-related genes and five reference genes) with the risk of developing an ipsilateral breast event was analyzed using Cox regression. [J Natl Cancer Inst] Full Article | Press Release

The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study
The authors examined whether lapatinib which binds both HER2 and EGFR could induce depletion of the EGFR-positive pool of circulating tumor cells (CTCs), which may in turn lead to clinical benefits. Patients with metastatic breast cancer and HER2 non-amplified primary tumors with EGFR-positive CTCs were recruited and lapatinib 1500 mg daily was administered, in a standard two step phase II trial. [PLoS One] Full Article

First-Line Treatment Patterns and Clinical Outcomes in Patients with HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer from RegistHER
The authors examined first-line treatment patterns and clinical outcomes in patients with HER2-positive, hormone receptor-positive metastatic breast cancer in a real-world setting. Progression-free survival and overall survival times were examined. [Oncologist] Abstract | Press Release

USF Gets $2.8M National Institutes of Health Grant with Aetna to Study Genetic Testing and Breast Cancer Treatment
The University of South Florida (USF) and Aetna are launching a ground-breaking study that will examine the influence genetic testing may have on clinical treatment decisions among breast cancer patients and their doctors. The study will follow 5,000 Aetna members from across the country who have been newly diagnosed with breast cancer and who are undergoing genetic testing. [University of South Florida]
Press Release

GW Receives $275,000 in Grants from the Avon Foundation
The Avon Foundation announced $275,000 in grants to The George Washington University (GW) School of Medicine and Health Sciences and GW Cancer Institute, at the close of the 11th annual Avon Walk for Breast Cancer in Washington, D.C. [George Washington University] Press Release

NIH Saves Lives: Fred Hutchinson Cancer Research Center Calls on Congress to Restore Full NIH Funding
Fred Hutchinson Cancer Research Center called on Congress to support restoring full funding to the National Institutes of Health (NIH), which supports pioneering research that saves lives. Funding was recently cut due to sequestration. [Fred Hutchinson Cancer Research Center]  Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW SELECTBIO CellTech 2014
January 28-29, 2014
San Diego, United States

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Fellow – Cancer Biomarkers (University of Bergen)

Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

Postdoctoral Fellow – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Breast Cancer Cell Research (Mount Sinai School of Medicine)

Research Associate (University of North Carolina at Charlotte, Department of Biology)

Postdoctoral Position – Breast Cancer (UT Southwestern Medical Center at Dallas)

Product Director – Breast Marketing (Genomic Health)

Postdoctoral Researcher – Cancer Genomics and Computational Biology/Bioinformatics (University of British Columbia/Provincial Health Services Authority)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.